TrialAnnals of oncology : official journal of the European Society for Medical Oncology2015

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

B H O'Neil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.